Lipidomics Moves to Center Stage of Biomedicine.
Lipidomics Moves to Center Stage of Biomedicine.
复制标题
DOI：
10.1093/function/zqac071
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
脂质（脂肪）构成人体组织中的大部分代谢物。它们包括成千上万的分子，包括维生素，激素和信号分子。脂质对于疫苗开发、药物和营养是必不可少的。脂质的动态通量反映了遗传、转录组和环境的影响。出于这个原因，它们在细胞和组织（包括人类队列样本）中的准确测量对于临床诊断、生物标志物发现和精准医学越来越感兴趣。除了生物标志物，它们还提供了有关疾病机制的信息，包括潜在的药物干预靶点。显然，如果我们要从人类疾病的角度利用它们的生物学，那么了解脂质代谢是必不可少的。为了支持这一想法，对脂质的了解已经开始揭示重要的机制见解，例如在心血管、阿尔茨海默病、帕金森病和癌症方面。2-5使用质谱法（MS）大规模分析脂质被称为“脂质组学”。这是指在单个样品中同时测量数十、数百甚至数千种分子种类。脂质组学在生物医学研究中迅速扩展，如人类队列分析所示。3然而，这导致了重大挑战，特别是在确保整个分析管道的数据质量方面，正如Harald K öfeler等人最近在这里强调的那样。这些包括LIPID MAPS，这是一种长期的生物医学资源，从2003年开始，开发了全球使用的脂质分类和命名系统（https：//lipidmaps. org/）。LIPID MAPS起源于美国加州圣地亚哥大学（UCSD），由Edward Dennis及其同事领导，并由NIH Glue Grant资助。在此之后，它于2016年作为Wellcome生物医学资源转移到英国，由我沿着与Babraham研究所的Michael Wakelam一起领导。从那时起，该资源在三个地点协同管理，卡迪夫，巴布拉罕和加州大学圣地亚哥分校。今天，我们继续运行脂质地图，从斯旺西的威廉格里菲斯和安德烈洛佩斯在
Lipids (fats) comprise the majority of metabolites in human tissues. They include thousands of molecules, including vitamins, hormones, and signaling molecules. Lipids are essential for vaccine development, pharmaceuticals, and nutrition. Dynamic fluxes in lipids reflect genetic, transcriptomic, and environmental impacts. For this reason, their accurate measurement in cells and tissues, including human cohort samples, is of increasing interest for clinical diagnostics, biomarker discovery, and precision medicine. 1 Beyond biomarkers, they provide information on disease mechanisms, including potential druggable targets for intervention. Clearly, understanding lipid metabolism is essential if we are to exploit their biology from a perspective of human disease. In support of this idea, understanding of lipids is already starting to reveal significant mechanistic insights, for example, in cardiovascular, Alzheimer’s, Parkinson’s diseases, and cancer. 2–5The analysis of lipids at scale using mass spectrometry (MS) is called “lipidomics.” This refers to the simultaneous measurement of tens, hundreds, or even thousands of molecular species in a single sample. Lipidomics is rapidly expanding in biomedical research, as exemplified by human cohort analysis. 3 However, this has led to significant challenges, especially in relation to ensuring data quality throughout the analytical pipeline, as recently highlighted here by Harald K öfeler et al. 6 To support lipidomics, several international initiatives exist. These include LIPID MAPS, the longstanding biomedical resource that starting in 2003, developed the globally used sys-tem for classification and nomenclature of lipids ( https://lipidm aps. org/). LIPID MAPS originated in the US, at the University of California San Diego (UCSD), led by Edward Dennis and colleagues, and funded by an NIH Glue Grant. Following this, it moved to the UK in 2016 as a Wellcome Biomedical Resource, with the grant award led by me along with Michael Wakelam of the Babraham Institute. From then, the resource was managed collaboratively across three sites, Cardiff, Babraham and UCSD. Today, we continue to run LIPID MAPS, with additional input from William Griffiths in Swansea and Andrea Lopez at